查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600142

海洋衍生药品市场：按来源、药物类型和最终用户划分 - 2025-2030 年全球预测

Marine Derived Drugs Market by Source (Algae, Invertebrates, Microorganisms), Drug Type (Analgesics, Anti-coagulants, Anti-inflammatory), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年海洋药物市场价值为41亿美元，预计到2024年将达到44.4亿美元，复合年增长率为8.70%，到2030年将达到73.6亿美元。

海洋源药物指从藻类、细菌、真菌、海绵、软体动物等海洋生物中提取或合成的药物。这些药物涵盖广泛的治疗应用，包括治疗癌症、感染疾病、心血管疾病和发炎。对海洋药物的需求在于其独特的生物活性化合物，这些化合物通常具有陆地生物中未发现的新颖作用机制。这些药物在製药和生物技术领域都有应用，最终用途包括医院、研究机构和药品製造商。

主要市场统计
基准年[2023] 41亿美元
预测年份 [2024] 44.4亿美元
预测年份 [2030] 73.6亿美元
复合年增长率（%） 8.70%

海洋药物市场受到海洋生物技术进步、海洋生物多样性研究资金增加以及对新疗法的需求迅速增加等因素的影响。慢性病盛行率的上升以及人们对海洋生物产品益处的认识不断增强，进一步推动了市场的成长。最近的商业机会包括审查未开发的海洋栖息地、促进学术界和工业界之间的合作以及开发可持续的提取技术。然而，挑战包括严格的法律规范、高昂的研发成本以及环境保护工作的不确定性。监管机构被要求透过简化流程和促进永续实践，将环境保护工作与药物开发结合。

未发现的海洋生物的生物勘探、改进药物输送系统以及合成受海洋启发的类似物等领域存在大量创新机会。专注于基因组学和代谢体学的富有洞察力的研究可以揭示复杂的海洋生物系统，并增加突破性药物发现的潜力。市场的本质是高度动态的，并由科学探索和商业性可行性相结合所驱动。希望在这一领域发展的公司可以透过投资跨学科研究、利用人工智慧进行资料分析以及充分利用全球研究合作来克服限制并获得该领域所需的专业知识。

市场动态：揭示快速发展的海洋衍生药品市场的关键市场洞察

供需的动态交互作用正在改变海洋药品市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界各地慢性病的盛行率
    • 政府和私营部门增加对海洋生物技术的投资
  • 市场限制因素
    • 海洋资源相关新药开发成本高
  • 市场机会
    • 海洋药物萃取和合成技术的不断进步
    • 人们越来越关注扩大海洋药物的治疗潜力
  • 市场问题
    • 有关海洋药物的环境和伦理问题

波特五力：驾驭海洋衍生药物市场的战略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对海洋药物市场的影响

外部宏观环境因素在塑造海洋药物市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解海洋药物市场的竞争格局

对海洋衍生药品市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：海洋衍生药品市场供应商的绩效评估

FPNV定位矩阵是评估海洋衍生药品市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划海洋药物市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对海洋药品市场进行策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境，主要企业的广泛资料，评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检验市场占有率、业务策略、产品系列、认证、核准核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地的慢性病盛行率正在上升
      • 增加政府和私人对海洋生物技术的投资
    • 抑制因素
      • 海洋资源相关新药开发成本高
    • 机会
      • 海洋药物萃取与合成技术发展
      • 扩大海洋药物的治疗潜力正引起越来越多的关注
    • 任务
      • 有关海洋药物的环境和伦理问题
  • 市场区隔分析
    • 来源：藻类的使用增加，尤其是在护肤品中
    • 最终用户：经监管部门核准，各医院海洋源药物的巨大潜力
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 海洋药物市场：依来源分类

  • 介绍
  • 藻类
  • 无脊椎动物
  • 微生物

第七章 海洋药物市场：依药物类型

  • 介绍
  • 止痛药
  • 抗凝血物
  • 发炎（药
  • 抗菌的
  • 抗病毒药
  • 抗癌药

第八章 海洋药物市场：依最终使用者分类

  • 介绍
  • 医院
  • 製药和生物技术公司
  • 研究/学术机构

第九章 美洲海洋药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太海洋衍生药品市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的海洋药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 加州大学圣地牙哥分校开发基于藻类的微型机器人技术，以增强肺部肿瘤的药物输送
    • GITAM 获得 136.9 亿印度卢比用于创新海洋药物发现中心，以对抗癌症和抗生素抗药性
  • 战略分析和建议

公司名单

  • Aker BioMarine ASA
  • Aphios Corporation
  • Eisai Co., Ltd.
  • Gimv NV
  • GlycoMar Limited
  • Marinova Pty Ltd.
  • Nereus Pharmaceuticals, Inc.
  • Perha Pharmaceuticals
  • Pfizer, Inc.
  • Pharma Mar, SA
  • TransAlgae
  • Zelnova Zeltia
Product Code: MRR-437A48C79EDF

The Marine Derived Drugs Market was valued at USD 4.10 billion in 2023, expected to reach USD 4.44 billion in 2024, and is projected to grow at a CAGR of 8.70%, to USD 7.36 billion by 2030.

Marine-derived drugs refer to pharmaceuticals that are extracted or synthesized from marine organisms, such as algae, bacteria, fungi, sponges, and mollusks. The scope of these drugs encompasses a wide range of therapeutic applications, including treatments for cancer, infections, cardiovascular diseases, and inflammation. The necessity for marine-derived drugs is driven by their unique bioactive compounds, which often offer novel mechanisms of action not found in terrestrial organisms. These drugs are applied in both pharmaceutical and biotechnology settings, with end-use scope including hospitals, research institutions, and pharmaceutical manufacturers.

KEY MARKET STATISTICS
Base Year [2023] USD 4.10 billion
Estimated Year [2024] USD 4.44 billion
Forecast Year [2030] USD 7.36 billion
CAGR (%) 8.70%

The market for marine-derived drugs is influenced by factors such as technological advancements in marine biotechnology, increased funding for marine biodiversity research, and a surge in demand for novel therapeutics. The rising incidence of chronic diseases and the growing awareness of the benefits of marine bioproducts further bolster market growth. Recent opportunities lie in the in-depth exploration of uncharted marine habitats, fostering collaborations partnerships between academia and industry, and the development of sustainable harvesting techniques. However, challenges include stringent regulatory frameworks, high research and development costs, and uncertainties related to environmental conservation efforts. There's a need for regulatory bodies to streamline processes and promote sustainable practices, aligning conservation efforts with pharmaceutical development.

Innovation opportunities abound in areas such as bioprospecting for undiscovered marine organisms, the improvement of drug delivery systems, and the synthesis of marine-inspired analogs. Insightful research can focus on genomics and metabolomics to unravel complex marine biosystems, advancing the potential for groundbreaking drug discoveries. The nature of the market is highly dynamic, driven by a combination of scientific inquiry and commercial viability. Companies aiming to grow in this space should invest in cross-disciplinary research, leverage artificial intelligence for data analysis, and engage in global collaborations to overcome limitations and maximize the expertise required in the field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Marine Derived Drugs Market

The Marine Derived Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases worldwide
    • Growing investments in marine biotechnologies by government and private authorities
  • Market Restraints
    • High cost of development of new drugs associated with marine sources
  • Market Opportunities
    • Increasing advances in extraction and synthesis technologies of marine derived drugs
    • Growing focus on expanding therapeutic potential of marine-derived drugs
  • Market Challenges
    • Environmental and ethical concerns with marine derived drugs

Porter's Five Forces: A Strategic Tool for Navigating the Marine Derived Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Marine Derived Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Marine Derived Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Marine Derived Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Marine Derived Drugs Market

A detailed market share analysis in the Marine Derived Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Marine Derived Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Marine Derived Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Marine Derived Drugs Market

A strategic analysis of the Marine Derived Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Marine Derived Drugs Market, highlighting leading vendors and their innovative profiles. These include Aker BioMarine ASA, Aphios Corporation, Eisai Co., Ltd., Gimv NV, GlycoMar Limited, Marinova Pty Ltd., Nereus Pharmaceuticals, Inc., Perha Pharmaceuticals, Pfizer, Inc., Pharma Mar, S.A., TransAlgae, and Zelnova Zeltia.

Market Segmentation & Coverage

This research report categorizes the Marine Derived Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Source, market is studied across Algae, Invertebrates, and Microorganisms.
  • Based on Drug Type, market is studied across Analgesics, Anti-coagulants, Anti-inflammatory, Anti-microbial, Anti-viral, and Anticancer.
  • Based on End-User, market is studied across Hospitals, Pharmaceutical & Biotechnology Companies, and Research & Academic Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing investments in marine biotechnologies by government and private authorities
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of development of new drugs associated with marine sources
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing advances in extraction and synthesis technologies of marine derived drugs
      • 5.1.3.2. Growing focus on expanding therapeutic potential of marine-derived drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Environmental and ethical concerns with marine derived drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Growing usage of algae especially in skincare products
    • 5.2.2. End-User: High potential of marine derived drugs across hospitals that have obtained regulatory approvals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Marine Derived Drugs Market, by Source

  • 6.1. Introduction
  • 6.2. Algae
  • 6.3. Invertebrates
  • 6.4. Microorganisms

7. Marine Derived Drugs Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Analgesics
  • 7.3. Anti-coagulants
  • 7.4. Anti-inflammatory
  • 7.5. Anti-microbial
  • 7.6. Anti-viral
  • 7.7. Anticancer

8. Marine Derived Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Research & Academic Institutions

9. Americas Marine Derived Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Marine Derived Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Marine Derived Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. UC San Diego Innovates Algae-Based Microbot Technology for Enhanced Lung Tumor Drug Delivery
    • 12.3.2. GITAM secures INR 13.69 crore for innovative marine drug discovery center to combat cancer and antibiotic resistance
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aker BioMarine ASA
  • 2. Aphios Corporation
  • 3. Eisai Co., Ltd.
  • 4. Gimv NV
  • 5. GlycoMar Limited
  • 6. Marinova Pty Ltd.
  • 7. Nereus Pharmaceuticals, Inc.
  • 8. Perha Pharmaceuticals
  • 9. Pfizer, Inc.
  • 10. Pharma Mar, S.A.
  • 11. TransAlgae
  • 12. Zelnova Zeltia

LIST OF FIGURES

  • FIGURE 1. MARINE DERIVED DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. MARINE DERIVED DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. MARINE DERIVED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. MARINE DERIVED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MARINE DERIVED DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MARINE DERIVED DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ALGAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY INVERTEBRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY MICROORGANISMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-COAGULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTI-VIRAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY ANTICANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MARINE DERIVED DRUGS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES MARINE DERIVED DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM MARINE DERIVED DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. MARINE DERIVED DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. MARINE DERIVED DRUGS MARKET, FPNV POSITIONING MATRIX, 2023